1 completed, 1 recruiting, 1 terminated, 1 withdrawn. 3 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Not applicable | 1 | Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Liraglutide Pen Injector: new trials by email Literature Review of Liraglutide Pen Injector trials Research Report on Liraglutide Pen Injector
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes Liraglutide Pen Injector, Saline Injections - Type 1 Diabetes, Type 2 Diabetes | Phase 2 | Recruiting | Mayo Clinic | 60 | 2025-10-03 | 2026-10-19 |
| Efficacy of Liraglutide Therapy in Patients With IPAA Liraglutide Pen Injector, Placebo Pen Injector - Pouchitis, Irritable Pouch Syndrome | Phase 2 | Terminated | University of North Carolina, Chapel Hill | 8 | 2022-03-22 | 2024-07-23 |
| Use of a GLP-1R Agonist to Treat Opioid Use Disorder Liraglutide Pen Injector, Placebo - Opiate Substitution Treatment, Opioid-Related Disorders | Phase 1 / Phase 2 | Completed | Milton S. Hershey Medical Center | 27 | 2021-10-18 | 2024-11-06 |
| Liraglutide for Low-responders After Bariatric Surgery Liraglutide Pen Injector - Obesity, Obesity, Morbid | Not applicable | Withdrawn | Zuyderland Medisch Centrum | 2020-12-21 | 2021-04-26 |
Diabetes Mellitus, Type 1 (1) · Diabetes Mellitus, Type 2 (1) · Obesity (1) · Obesity, Morbid (1) · Opioid-Related Disorders (1) · Pouchitis (1) · Weight Loss (1)
Mayo Clinic (1) · Milton S. Hershey Medical Center (1) · University of North Carolina, Chapel Hill (1) · Zuyderland Medisch Centrum (1)
United States (3)
Adrian Vella, MD (1) · Hans Herfarth, MD, PhD (1) · J.W. Greve, MD, PHD (1) · Scott Bunce, PhD (1)
1UG3DA050325-01 (1)